SCHEMBL4792454

SCHEMBL4792454

CSC1=N/C(=C\c2c[nH]c3ncc([N+](=O)[O-])cc23)C(=O)N1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 2/20 0.39
▸ GAA P10253 1/20 0.39
▸ HPGD P15428 2/20 0.38
▸ DYRK1A Q13627 3/20 0.38
▸ DYRK1B Q9Y463 3/20 0.38
▸ DYRK3 O43781 2/20 0.38
▸ PIM1 P11309 2/20 0.38
▸ CSNK2A2 P19784 2/20 0.38
▸ CSNK2B P67870 2/20 0.38
▸ CSNK2A1 P68400 2/20 0.38
▸ CSNK2A3 Q8NEV1 2/20 0.38
▸ DYRK2 Q92630 2/20 0.38
▸ CNR1 P21554 1/20 0.35
▸ CNR2 P34972 1/20 0.35
▸ GPR18 Q14330 1/20 0.35
▸ KDM4E B2RXH2 2/20 0.34
▸ RET P07949 1/20 0.33
▸ PARP1 P09874 1/20 0.32
▸ MEN1 O00255 1/20 0.31
▸ KMT2A Q03164 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4792456 1.00 MAPT (0.39) MAPTGAAHPGDDYRK1ADYRK1B
SCHEMBL1714289 0.83 GPR18 (0.43) MAPTGAAHPGDDYRK1ADYRK1B
SCHEMBL1714283 0.83 GPR18 (0.43) MAPTGAAHPGDDYRK1ADYRK1B
SCHEMBL5094606 0.79 MAPT (0.39) MAPTGAAHPGDDYRK1ADYRK1B
SCHEMBL5094604 0.79 MAPT (0.39) MAPTGAAHPGDDYRK1ADYRK1B
SCHEMBL5089591 0.76 SMN1; SMN2 (0.44) MAPTGAARETMEN1KMT2A
SCHEMBL5089603 0.76 SMN1; SMN2 (0.44) MAPTGAARETMEN1KMT2A
SCHEMBL5092683 0.76 SMN1; SMN2 (0.44) MAPTGAARETMEN1KMT2A
SCHEMBL5100901 0.76 CHEK1 (0.52) MAPTGAAHPGDDYRK1ADYRK1B
SCHEMBL5100892 0.76 CHEK1 (0.52) MAPTGAAHPGDDYRK1ADYRK1B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1960399-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS Pfizer Italia S.r.l. (IT) 2008-08-27 — — EP disclosed
US-7371862-B2 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PFIZER ITALIA S.R.L. (IT) 2008-05-13 — — US disclosed
WO-2007054508-A1 PYRROLOPYRIDINES AS KINASE INHIBITORS PFIZER ITALIA SRL (IT) 2007-05-18 — — WO disclosed
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them PHARMACIA ITALIA S.P.A. (IT) 2007-05-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070112020-A1 Azaindolylidene derivatives as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them MAP3K20, MAP3K6, MAP3K1 MAPT 1665/4885GAA 972/4885HPGD 1179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback